Presentation and Status in Health Basket
1 X 1.5 ml X 10 mg/1.5 ml
1 X 1.5 ml X 15 mg/1.5 ml
Generally recommended dosages:
Children: Growth hormone insufficiency 25-35 μg/kg/day or 0.7-1.0 mg/m²/day When GHD persists after growth completion, growth hormone treatment should be continued to achieve full somatic adult development including lean body mass and bone mineral accrual (for guidance on dosing, see Replacement therapy in adults).
Turner syndrome: 45-67 μg/kg/day or 1.3-2.0 mg/m²/day Pediatric patients with short stature associated with Noonan syndrom
Not all patients with Noonan syndrome have short stature, some will achieve a normal adult hight without treatment. Therefore prior to initiating Norditropin® for a patient with Noonan syndrom, establish that the patient does have short stature. A dosage of up to 0.066 mg/kg/day is recommended.
Chronic Renal Disease: 50 μg/kg/day or 1.4 mg/m²/day
Small for gestational age:m35 microgram/kg/day or 1 milligram /m²/day A dose of 0.035 mg/kg/day is usually recommended until final height is reached Treatment should be discontinued after the first year of treatment, if the height velocity SDS is below +1.
Treatment should be discontinued if height velocity is < 2cm/year and, if confirmation is required, bone age is>14 years (girls) or >16 years (boys), corresponding to closure of the epiphyseal growth plates.
Replacement therapy in adults: The dosage must be adjusted to the need of the individual patient.In patients with childhood onset GHD, the recommended dose to restart is 0.2-0.5 mg/day with subsequent dose adjustment on the basis of IGF-I concentration determination.
In patients with adult onset GHD it is recommended to start treatment with a low dose 0.1-0.3 mg/day. It is recommended to increase the dosage gradually at monthly intervals based on the clinical response and the patient’s experience of adverse events. Serum insulin-like growth factor I (IGF-I) can be used as guidance for the dose titration. Women may require higher doses than men, with men showing an increasing IGF-I sensitivity over time. This means that there is a risk that women, especially those on oral oestrogen replacement are under-treated while men are overtreated. Dose requirements decline with age. Maintenance dosage varies considerably from person to person, but seldom exceeds 1.0 mg/day. Generally, daily subcutaneous administration in the evening is recommended. The injection site should be varied to prevent lipoatrophy.
Children: Short stature due to inadequate or failed secretion of pituitary growth hormone or Turners syndrome. Short stature in children with renal insufficiency. Growth disturbance (current height SDS < – 2.5 and parental adjusted height SDS < – 1) in short children born small for gestational age (SGA) with a birth weight and/or length below – 2 SD who failed to show catch-up growth (HV SDS< 0 during the last year) by 4 years of age or later. Children with short stature associated with Noonan syndrome.
Adults: Treatment of adults with Hypothalamic-pituitary disease resulting from organic disease or pituitary tumors treated medically surgically or radiotherapy or patients with chilhood onset of G.H. deficiency.
Hypersensitivity to the active substance or to any of the excipients. Somatropin must not be used when there is any evidence of activity of a tumour. Intracranial tumours must be inactive and antitumour therapy must be completed prior to starting growth hormone (GH) therapy. Treatment should be discontinued if there is evidence of tumour growth. Somatropin should not be used for longitudinal growth promotion in children with closed epiphyses. Patients with acute critical illness suffering complications following open heart surgery, abdominal surgery, multiple accidental trauma, acute respiratory failure or similar conditions should not be treated with somatropin. In the children with chronic renal disease treatment with Norditropin should be discontinued at renal transplantation.
Children treated with somatropin should be regularly assessed by a specialist in child growth. Somatropin treatment should always be instigated by a physician with special knowledge of growth hormone insufficiency and its treatment. This is true also for the management of Turner syndrome and chronic renal disease and SGA. Data of final adult height following the use of Norditropin for children with chronic renal disease are not available. The maximum recommended daily dose should not be exceeded. The stimulation of longitudinal growth in children can only be expected until epiphysial closure. Treatment of growth hormone deficiency in patients with Prader-Willi syndrome There have been reports of sudden death after initiating somatropin therapy in patients with Prader-Willi syndrome, who had one or more of the following risk factors: severe obesity, history of upper airway obstruction or sleep apnoea, or unidentified respiratory infection.
Growth hormone deficiency in adults: Growth hormone deficiency in adults is a lifelong disease and needs to be treated accordingly. However, experience in patients older than 60 years and in patients with more than five years of treatment in adult growth hormone deficiency is still limited.
Small for Gestational Age: In short children born SGA other medical reasons or treatments that could explain growth disturbance should be ruled out before starting treatment. Experience in initiating treatment in SGA patients near onset of puberty is limited. It is therefore not recommended to initiate treatment near onset of puberty. Experience with patients with Silver-Russell syndrome is limited.
Turner syndrome: Monitoring of growth of hands and feet in Turner syndrome patients treated withm somatropin is recommended and a dose reduction to the lower part of the dose range should be considered if increased growth is observed. Girls with Turner syndrome generally have an increased risk of otitis media, which is why otological evaluation is recommended on at least an annual basis.
Chronic renal disease: The dosage in children with chronic renal disease is individual and must be adjusted according to the individual response to therapy. The growth disturbance should be clearly established before somatropin treatment by following growth on optimal treatment for renal disease over one year. Conservative management of uraemia with customary medicinal product, and if needed dialysis, should be maintained during somatropin therapy. Patients with chronic renal disease normally experience a decline in renal function as part of the natural course of their illness. However, as a precautionary measure during somatropin treatment, renal function should be monitored for an excessive decline, or increase in the glomerular filtration rate (which could imply hyperfiltration).
Tumours and malignancies: In patients in complete remission from tumours or malignant disease, somatropin growth hormone therapy has not been associated with an increased relapse rate. Nevertheless, patients who have achieved complete remission of malignant disease should be followed closely for relapse after commencement of Norditropin therapy.
Leukaemia: Leukaemia has been reported in a small number of growth hormone deficiency patients, some of whom have been treated with somatropin. However, there is no evidence that leukaemia incidence is increased in somatropin recipients without predisposition factors.
Benign intracranial hypertension: In the event of severe or recurrent headache, visual problems, nausea, and/or vomiting, a funduscopy for papilloedema is recommended. If papilloedema is confirmed, a diagnosis of benign intracranial hypertension should be considered and if appropriate the somatropin treatment should be discontinued. At present there is insufficient evidence to guide clinical decision making in patients with resolved intracranial hypertension. If somatropin treatment is restarted, careful monitoring for symptoms of intracranial hypertension is necessary. Patients with growth hormone deficiency secondary to an intracranial lesion should be examined frequently for progression or recurrence of the underlying disease process.
Thyroid function: Somatropin increases the extrathyroidal conversion of T4 to T3 and may, as such, unmask incipient hypothyroidism. Monitoring of thyroid function should therefore be conducted in all patients. In patients with hypopituitarism, standard replacement therapy
must be closely monitored when somatropin therapy is administered. In patients with a pituitary disease in progression, hypothyroidism may develop. Patients with Turner syndrome have an increased risk of developing primary hypothyroidism associated with anti-thyroid antibodies. As hypothyroidism interferes with the response to somatropin therapy patients should have their thyroid function tested regularly, and should receive replacement therapy with thyroid hormone when indicated.
Scoliosis: Scoliosis may progress in any child during rapid growth. Signs of scoliosis should be monitored during treatment. However, somatropin treatment has not been shown to increase the incidence or severity of scoliosis.
Insulin sensitivity: Because somatropin may reduce insulin sensitivity, patients should be monitored for evidence of glucose intolerance. For patients with diabetes mellitus, the insulin dose may require adjustment after somatropin containing product therapy instituted. Patients with diabetes or glucose intolerance should be monitored closely during somatropin therapy.
Blood glucose and insulin: In Turner syndrome and SGA children it is recommended to measure fasting insulin and blood glucose before start of treatment and annually thereafter. In patients with increased risk of diabetes mellitus (e.g. familial history of diabetes, obesity, severe insulin resistance, acanthosis nigricans) oral glucose tolerance testing (OGTT) should be performed. If overt diabetes occurs, somatropin should not be administered. Somatropin has been found to influence carbohydrate metabolism, therefore, patients should be observed for evidence of glucose intolerance.
IGF-I: In Turner syndrome and SGA children it is recommended to measure the IGF-I level before start of treatment and twice a year thereafter. If on repeated measurements IGF-I levels exceed +2 SD compared to references for age and pubertal status, the dose should be reduced to achieve an IGF-I level within the normal range. Some of the height gain obtained with treating short children born SGA with somatropin may be lost if treatment is stopped before final height is reached.Antibodies As with all somatropin containing products, a small percentage of patients may develop antibodies to somatropin. The binding capacity of these antibodies is low and there is no effect on growth rate. Testing for antibodies to somatropin should be carried out in any patient who fails to respond to therapy.
Clinical trial experience: Two placebo-controlled clinical trials of patients in intensive care units have demonstrated an increased mortality among patients suffering from acute critical illness due to complications following open heart or abdominal surgery, multiple accidental trauma or acute respiratory failure, who were treated with somatropin in high doses (5.3 – 8 mg/day). The safety of continuing somatropin treatment in patients receiving replacement doses for approved indications who concurrently develop these illnesses has not been established. Therefore, the potential benefit of treatment continuation with somatropin in patients having acute critical illnesses should be weighed against the potential risk. One open-label, randomised clinical trial (dose range 45-90 μg/kg/day) with patients with Turner syndrome indicated a tendency for a dose-dependent risk of otitis externa and otitis media. The increase in ear infections did not result in more ear operations/ tube insertions compared to the lower dose group in the trial.
See prescribing information for full details.
Growth hormone deficient patients are characterised by extracellular volume deficit. When treatment with somatropin is initiated, this deficit is corrected. Fluid retention with peripheral oedema may occur especially in adults. Carpal tunnel syndrome is uncommon, but may be seen in adults. The symptoms are usually transient, dose dependant and may require transient dose reduction. Mild arthralgia, muscle pain and paresthesia may also occur, but are usually self-limiting. Adverse reactions in children are uncommon or rare.
See prescribing information for full details.
Concomitant glucocorticoid therapy may inhibit growth and thereby oppose the growth promoting effect. The effect of growth hormone on final height can also be influenced by additional therapy with other hormones, e.g. gonadotrophin, anabolic steroids, estrogen and thyroid hormone.
Pregnancy and Lactation
Pregnancy: Animal studies are insufficient with regard to effects on pregnancy, embryofoetal development, parturition or postnatal development. No clinical data on exposed pregnancies are available. Therefore, somatropin containing products are not recommended during pregnancy and in women childbearing potential not using contraception.
Lactation: There have been no clinical studies conducted with somatropin containing products in breast-feeding women. It is not known whether somatropin is excreted in human milk. Therefore caution should be exercised when somatropin containing products are administered to breast-feeding women.
Acute over dosage can lead to low blood glucose levels initially, followed by high blood glucose levels. These decreased glucose levels have been detected biochemically, but without clinical signs of hypoglycemia. Long-term over dosage could result in signs and symptoms consistent with the known effects of human growth hormone excess.